Daily-Dose/archive-covid-19/18 May, 2021.html

223 lines
56 KiB
HTML
Raw Normal View History

2021-05-18 13:59:33 +01:00
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>18 May, 2021</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Systematic Review and Meta-analysis on COVID-19 Vaccine Hesitancy</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: The presented meta-analysis was developed in response to the publication of several studies addressing COVID-19 vaccines hesitancy. We aimed to identify the proportion of vaccine acceptance and rejection, and factors affecting vaccine hesitancy worldwide especially with the fast emergency approval of vaccines. Methods: Online database search was performed, and relevant studies were included with no language restriction. A meta-analysis was conducted using R software to obtain the random effect model of the pooled prevalence of vaccine acceptance and rejection. Egger regression test was performed to assess publication bias. Quality assessment was assessed using Newcastle-Ottawa Scale quality assessment tool. Results: Thirty-nine out of 12246 articles met the predefined inclusion criteria. All studies were cross-sectional designs. The pooled proportion of COVID-19 vaccine hesitancy was 17% (95% CI: 14-20) while the pooled proportion of COVID-19 vaccine acceptance was 75% (95% CI: 71-79). The vaccine hesitancy and the vaccine acceptance showed high heterogeneity (I 2 =100%). Case fatality ratio and the number of reported cases had significant effect on the vaccine acceptance as the pooled proportion of vaccine acceptance increased by 39.95% (95% CI: 20.1-59.8) for each 1% increase in case fatality (P&lt;0.0001) and decreased by 0.1% (95% CI: -0.2-0.01) for each 1000 reported case of COVID-19, P= 0.0183). Conclusion: Transparency in reporting the number of newly diagnosed COVID-19 cases and deaths is mandatory as these factors are the main determinants of COVID-19 vaccine acceptance.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.15.21257261v1" target="_blank">Systematic Review and Meta-analysis on COVID-19 Vaccine Hesitancy</a>
</div></li>
<li><strong>Controlling risk of SARS-CoV-2 infection in essential workers of enclosed food manufacturing facilities</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The SARS-CoV-2 global pandemic poses significant health risks to workers who are essential to maintaining the food supply chain. Using a quantitative risk assessment model, this study characterized the impact of risk reduction strategies for controlling SARS-CoV-2 transmission (droplet, aerosol, fomite-mediated) among front-line workers in a representative enclosed food manufacturing facility. We simulated: 1) individual and cumulative SARS-CoV-2 infection risks from close contact (droplet and aerosols at 1-3m), aerosol, and fomite-mediated exposures to a susceptible worker following exposure to an infected worker during an 8h-shift; and 2) the relative reduction in SARS-CoV-2 infection risk attributed to infection control interventions (physical distancing, mask use, ventilation, surface disinfection, hand hygiene). Without mitigation measures, the SARS-CoV-2 infection risk was largest for close contact (droplet and aerosol) at 1m (0.96, 95%CI: 0.67-1.0). In comparison, risk associated with fomite (0.26, 95%CI: 0.10-0.56) or aerosol exposure alone (0.05, 95%CI: 0.01-0.13) at 1m distance was substantially lower (73-95%). At 1m, droplet transmission predominated over aerosol and fomite-mediated transmission, however, this changed by 3m, with aerosols comprising the majority of the exposure dose. Increasing physical distancing reduced risk by 84% (1 to 2m) and 91% (1 to 3m). Universal mask use reduced infection risk by 52-88%, depending on mask type. Increasing ventilation (from 0.1 to 2-8 air changes/hour) resulted in risk reductions of 14-54% (1m) and 55-85% (2m). Combining these strategies, together with handwashing and surface disinfection, resulted in &lt;1% infection risk. Current industry SARS-CoV-2 risk reduction strategies, particularly when bundled, provide significant protection to essential food workers.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.14.21257244v1" target="_blank">Controlling risk of SARS-CoV-2 infection in essential workers of enclosed food manufacturing facilities</a>
</div></li>
<li><strong>Prediction of the effective reproduction number of COVID-19 in Greece. A machine learning approach using Google mobility data.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
This paper demonstrates how a short-term prediction of the effective reproduction number (Rt) of COVID-19 in regions of Greece is achieved based on online mobility data. Various machine learning methods are applied to predict Rt and attribute importance analysis is performed to reveal the most important variables that affect the accurate prediction of Rt. Our results are based on an ensemble of diverse Rt methodologies to provide non-precautious and non-indulgent predictions. The model demonstrates robust results and the methodology overall represents a promising approach towards COVID-19 outbreak prediction. This paper can help health related authorities when deciding non-nosocomial interventions to prevent the spread of COVID-19.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.14.21257209v1" target="_blank">Prediction of the effective reproduction number of COVID-19 in Greece. A machine learning approach using Google mobility data.</a>
</div></li>
<li><strong>Non-differential risk of SARS-CoV-2 infection for members of polling stations on Catalan parliament voting day.</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
We aimed to assess the risk of SARS-CoV-2 infection for polling station members during the Catalan elections in February 2021. We compared the incidence 14 days after the elections between a cohort of polling station members (N= 18,304) and a control cohort paired by age, sex and place of residence. A total of 37 COVID-19 cases (0.2%) were confirmed in the members of the polling stations and 43 (0.23%) in the control group (p-value 0.576). Our study suggests that there was no greater risk of infection for the members of the polling stations.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.13.21257143v1" target="_blank">Non-differential risk of SARS-CoV-2 infection for members of polling stations on Catalan parliament voting day.</a>
</div></li>
<li><strong>A novel deterministic epidemic model considering mass vaccination and lockdown against Covid-19 spread in Israel: Numerical study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Why public health intervention by Israel government against COVID-19 spread has been successful while the most countries in the world is still coping with it? To give the answer, a simple numerical epidemic model is prepared to simulate an entire trend of various infection related variables considering vaccination campaign and simultaneous lockdown. The model is an extension of the deterministic physical model ATLM previously published by the authors that aims to predict an entire trend of variables in a single epidemic. The time series data of both vaccine dose ratio and lockdown period are employed in the model. Predictions have been compared with observed data in terms of daily new cases, isolated people, infectious at large and effective reproductive number and the model is verified. Moreover, parameter survey calculations for several scenarios have clarified a synergy effect of vaccination and lockdown have existed. In particular, it is suggested the key element of Israel success lies in a high dose rate of vaccination that avoids the onset of the rebound of daily new cases on the rescission of the lockdown.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.15.21257264v1" target="_blank">A novel deterministic epidemic model considering mass vaccination and lockdown against Covid-19 spread in Israel: Numerical study</a>
</div></li>
<li><strong>Occupation, Work-Related Contact, and SARS-CoV-2 Anti-Nucleocapsid Serological Status: Findings from the Virus Watch prospective cohort study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Workers differ in their risk of acquiring SARS-CoV-2 infection according to their occupation; however, few studies have been able to control for multiple confounders or investigate the work-related factors that drive differences in occupational risk. Using data from the Virus Watch community cohort study in England and Wales, we set out to estimate the total effect of occupation on SARS-CoV-2 serological status, whether this is mediated by frequency of close contact within the workplace, and how exposure to poorly ventilated workplaces varied across occupations. Methods: We used data from a sub-cohort (n =3761) of adults (≥18) tested for SARS-CoV-2 anti-nucleocapsid antibodies between 01 February-28 April 2021 and responded to a questionnaire about work during the pandemic. Anti-nucleocapsid antibodies were used as a proxy of prior natural infection with COVID-19. We used logistic decomposition to estimate the total and direct effect of occupation and indirect effect of workplace contact frequency on odds of seropositivity, adjusting for age, sex, household income and region. We investigated the relationship between occupation and exposure to poorly-ventilated workplace environments using ordinal logistic regression. Results: Seropositivity was 16.0% (113/707) amongst workers with daily close contact, compared to 12.9% (120/933) for those with intermediate-frequency contact and 9.6% (203/2121) for those with no work-related close contact. Healthcare (OR= 2.14, 95% CI 1.47,3.12), indoor trade, process and plant (2.09, 1.31,3.33), leisure and personal service (1.96, 1.004,3.84), and transport and mobile machine (2.17, 1.12,4.18) workers had elevated total odds of SARS-CoV-2 seropositivity compared to other professional and associate occupations. Frequency of workplace contact accounted for a variable part of the increased odds in different occupational groups (OR range 1.04 [1.0004,1.07] - 1.22 [1.07, 1.38]). Healthcare workers and indoor trades and process plant workers continued to have raised odds of infection after accounting for work-related contact, and also had had greater odds of frequent exposure to poorly-ventilated workplaces (respectively 2.15 [1.66, 2.79] and (1.51, [1.12, 2.04]). Discussion: Marked variations in occupational odds of seropositivity remain after accounting for age, sex, region, and household income. Close contact in the workplace appears to contribute substantially to this variation. Reducing frequency of workplace contact is a critical part of COVID-19 control measures.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.13.21257161v1" target="_blank">Occupation, Work-Related Contact, and SARS-CoV-2 Anti-Nucleocapsid Serological Status: Findings from the Virus Watch prospective cohort study</a>
</div></li>
<li><strong>A Time Series Analysis and Forecast of COVID-19 Healthcare Disparity</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
This work focuses on a time series analysis and forecast of COVID 19. Decision makers and medical providers will find the work useful in improving cares to the disadvantaged demography, reduce the spread of the coronavirus and improve mitigation strategy to combat the impact of the disease. Our anatomy of COVID cases spans March 2020 to December 2020. COVID 19 forecasting cases and deaths models were built for the total population and blacks in eight states in the USA. State with medium to large populations of blacks were considered for the experiment. We defined COVID-19 Health Care Disparity (CHCD) as the difference between the percentage of Black Cases to Total Cases and Black Deaths to Total Deaths within a period. We hypothesized that a disparity exists if the ratio of black cases to the total COVID-19 population in a state, is less than the ratio of black deaths to the total deaths in the same state. The outcome of our experiment shows that there exists COVID-19 Health Care Disparity in the black community. Furthermore, all things being equal, our forecast suggests that the COVID-19 Health Care Disparities will continue at least till the end of the first quarter of 2021.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.13.21257189v1" target="_blank">A Time Series Analysis and Forecast of COVID-19 Healthcare Disparity</a>
</div></li>
<li><strong>Combined association of obesity and other cardiometabolic diseases with severe COVID-19 outcomes: a nationwide cross-sectional study of 21,773 Brazilian adult and elderly inpatients</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: To investigate the combined association of obesity, diabetes mellitus (DM), and cardiovascular disease (CVD) with severe COVID-19 outcomes in adult and elderly inpatients. Design: Cross-sectional study based on registry data from Brazil9s influenza surveillance system. Setting: Public and private hospitals across Brazil. Participants: Eligible population included 21,942 inpatients aged 20 years or older with positive RT-PCR test for SARS-CoV-2 until Jun 9th, 2020. Main outcome measures: Severe COVID-19 outcomes were non-invasive and invasive mechanical ventilation use, ICU admission, and death. Multivariate analyses were conducted separately for adults (20-59 years) and elders (&gt;=60 years) to test the combined association of obesity (without and with DM and/or CVD) and degrees of obesity with each outcome. Results: A sample of 8,848 adults and 12,925 elders were included. Among adults, obesity with DM and/or CVD showed higher prevalence of invasive (PR 3.76, 95%CI 2.82-5.01) and non-invasive mechanical ventilation use (2.06, 1.58-2.69), ICU admission (1.60, 1.40-1.83), and death (1.79, 1.45-2.21) compared with the group without obesity, DM, and CVD. In elders, obesity alone (without DM and CVD) had the highest prevalence of ICU admission (1.40, 1.07-1.82) and death (1.67, 1.00-2.80). In both age groups, obesity alone and combined with DM and/or CVD showed higher prevalence in all outcomes than DM and/or CVD. A dose-response association was observed between obesity and death in adults: class I 1.32 (1.05-1.66), class II 1.41 (1.06-1.87), and class III 1.77 (1.35-2.33). Conclusions: The combined association of obesity, diabetes, and/or CVD with severe COVID-19 outcomes may be stronger in adults than in elders. Obesity alone and combined with DM and/or CVD had more impact on the risk of COVID-19 severity than DM and/or CVD in both age groups. The study also supports an independent relationship of obesity with severe outcomes, including a dose-response association between degrees of obesity and death in adults. These findings suggest important implications for the clinical care of patients with obesity and severe COVID-19 and support the inclusion of people with obesity in the high-risk and vaccine priority groups for protection from SARS-CoV-2.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.14.21257204v1" target="_blank">Combined association of obesity and other cardiometabolic diseases with severe COVID-19 outcomes: a nationwide cross-sectional study of 21,773 Brazilian adult and elderly inpatients</a>
</div></li>
<li><strong>Racism, Posttraumatic Stress Symptoms, and Racial Disparity in the U.S. COVID-19 Syndemic</strong> -
<div>
The COVID-19 syndemic, with a disproportionately higher adverse impact on communities of color (i.e., COVID-19 infection and death), will likely exacerbate the existing health disparities in trauma-related symptoms between people of color (POC) and White Americans. However, no studies have examined the racial disparities in posttraumatic stress symptoms (PTSS) during COVID-19. Grounded in ecological theory and racial trauma framework, we investigated rates of racial disparities in PTSS and three possible mechanisms, 1) COVID stress, 2) direct racism, and 3) indirect racism, for these discrepancies using a large U.S. national sample (N = 2,019). Results indicated that POC reported higher levels of PTSS than White Americans (d =.21). The PTSS racial disparity was accounted more by direct and indirect racism than by the COVID-19-specific stressors, after controlling for age, gender, education, income, parent status, adverse childhood experiences (ACEs), and intimate partner violence (IPV). Additional fine-grained analyses for Hispanic/Latinx Americans (n = 283), Black/African Americans (n = 279), and Asian American and Pacific Islanders (n = 123) by and large corroborated the above findings. Our findings highlighted the deleterious impact of the ongoing racism pandemic on the POC community as a public health crisis in addition to the COVID-19 pandemic.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/rc2ns/" target="_blank">Racism, Posttraumatic Stress Symptoms, and Racial Disparity in the U.S. COVID-19 Syndemic</a>
</div></li>
<li><strong>The impact of the COVID-19 pandemic on the employment situation and financial well-being of families with children in Austria: Evidence from the first ten months of the crisis</strong> -
<div>
Objective: This study investigates the impact of the COVID-19 pandemic on the employment situation of parents and in turn on the subjective financial well-being of families with children in Austria. Background: The pandemic had strong repercussions on the Austrian labour market. The short-time work (STW) programme covered a third of employees in the first half of 2020 and helped to maintain employment levels. We provide evidence on how an unprecedented labour market crisis of this sort and in particular the exceptionally wide use of STW had affected the (gendered) employment situation of parents and the financial well-being of different types of families. Method: The study draws on representative panel survey data that cover 905 families with underage children. The data include information on the employment situation and financial well-being of single and cohabiting parents before the onset of the crisis, three months and ten months after its onset. Results: In contrast to other countries, mothers were not more strongly affected by the labour market crisis of 2020 than childless women or fathers. About a third of couples with underage children experienced income losses. Despite the wide use of STW and government support to families, the share of families in financial difficulties has substantially increased, especially among those with many children and single parents, many of who were at risk of poverty already before the crisis. Conclusion: Substantial shares of dual-earner families that had low poverty risks before the crisis were in financial difficulties in 2020. Potential spill-over effects of financial shocks on children are discussed.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/r7ugz/" target="_blank">The impact of the COVID-19 pandemic on the employment situation and financial well-being of families with children in Austria: Evidence from the first ten months of the crisis</a>
</div></li>
<li><strong>“How do we do this at a distance?!” A descriptive study of remote undergraduate research programs during COVID-19</strong> -
<div>
The COVID-19 pandemic shut down undergraduate research programs across the U.S. Twenty-three sites offered remote undergraduate research programs in the life sciences during summer 2020. Given the unprecedented offering of remote research experiences, we carried out a study to describe and evaluate these programs. Using structured templates, we documented how programs were designed and implemented, including who participated. Through focus groups and surveys, we identified programmatic strengths and shortcomings as well as recommendations for improvements from the perspectives of participating students. Strengths included the quality of mentorship, opportunities for learning and professional development, and development of a sense of community. Weaknesses included limited cohort building, challenges with insufficient structure, and issues with technology. Although all programs had one or more activities related to diversity, equity, inclusion, and justice, these topics were largely absent from student reports even though programs coincided with a peak in national consciousness about racial inequities and structural racism. Our results provide evidence for designing remote REUs that are experienced favorably by students. Our results also indicate that remote REUs are sufficiently positive to further investigate their affordances and constraints, including the potential to scale up offerings, with minimal concern about disenfranchising students.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.05.17.443632v1" target="_blank">“How do we do this at a distance?!” A descriptive study of remote undergraduate research programs during COVID-19</a>
</div></li>
<li><strong>Targeted redesign of suramin analogs for novel antimicrobial lead development</strong> -
<div>
The emergence of new viral infections and drug resistant bacteria urgently necessitates expedient therapeutic development. Repurposing and redesign of existing drugs against different targets is one potential way in which to accelerate this process. Suramin was initially developed as a successful anti-parasitic drug, but has also shown promising antiviral and antibacterial activities. However, due to its high conformational flexibility and negative charge, suramin is considered quite promiscuous towards positively charged sites within nucleic acid binding proteins. Although some suramin analogs have been developed against specific targets, only limited structure activity relationship (SAR) studies were performed, and virtual screening has yet to be used to identify more specific inhibitor(s) based on its scaffold. Using available structures, we investigated suramins target diversity, confirming that suramin preferentially binds to protein pockets which are both positively charged and enriched in aromatic or leucine residues. Further, suramins high conformational flexibility allows adaptation to structurally diverse binding surfaces. From this platform, we developed a framework for structure- and docking-guided elaboration of suramin analog scaffolds using virtual screening of suramin and heparin analogs against a panel of diverse therapeutically relevant viral and bacterial protein targets. Use of this new framework to design potentially specific suramin analogs is exemplified using the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and nucleocapsid protein, identifying leads that might inhibit a wide range of coronaviruses. The approach presented here establishes a new computational framework for designing suramin analogs against different bacterial and viral targets and repurposing existing drugs for more specific inhibitory activity.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.05.17.444489v1" target="_blank">Targeted redesign of suramin analogs for novel antimicrobial lead development</a>
</div></li>
<li><strong>High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19</strong> -
<div>
The COVID-19 pandemic, which is caused by SARS-CoV-2 has rapidly spread to more than 222 countries and has put global public health at high risk. The world urgently needs safe, a cost-effective SARS-CoV-2 coronavirus vaccine, therapeutic and antiviral drugs to combat the COVID-19. Angiotensin-converting enzyme 2 (ACE2), as a key receptor for SARS-CoV-2 infections, has been proposed as a potential therapeutic target in COVID-19 patients. In this study, we report high level production (about ~0.75 g /kg leaf biomass) of glycosylated and non-glycosylated forms of recombinant human truncated ACE2 in Nicotiana benthamiana plant. The plant produced recombinant human truncated ACE2s successfully bind to the SARC-CoV-2 spike protein, but deglycosylated ACE2 binds more strongly than the glycosylated counterpart. Importantly, both deglycosylated and glycosylated forms of AEC2 stable at elevated temperatures for prolonged periods and demonstrated strong anti-SARS-CoV-2 activity in vitro. The IC50 values of glycosylated and deglycosylated AEC2 were 0.4 and 24 g/ml, respectively, for the pre-entry infection, when incubated with 100TCID50 of SARS-CoV-2. Thus, plant produced truncated ACE2s are promising cost-effective and safe candidate as a potential therapeutic targets in the treatment of COVID-19 patients.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.05.17.444533v1" target="_blank">High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19</a>
</div></li>
<li><strong>Sociodemographic inequality in COVID-19 vaccination coverage amongst elderly adults in England: a national linked data study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: To examine inequalities in COVID-19 vaccination rates amongst elderly adults in England Design: Cohort study Setting: People living in private households and communal establishments in England Participants: 6,829,643 adults aged 70 years or above (mean 78.7 years, 55.2% female) who were alive on 15 March 2021. Main outcome measures: Having received the first dose of a vaccine against COVID-19 by 15 March 2021. We calculated vaccination rates and estimated unadjusted and adjusted odds ratios using logistic regression models. Results: By 15 March 2021, 93.2% of people living in England aged 70 years and over had received at least one dose of a COVID-19 vaccine. While vaccination rates differed across all factors considered apart from sex, the greatest disparities were seen between ethnic and religious groups. The lowest rates were in people of Black African and Black Caribbean ethnic backgrounds, where only 67.2% and 73.9% had received a vaccine, with adjusted odds of not being vaccinated at 5.01 (95% CI 4.86 - 5.16) and 4.85 (4.75 - 4.96) times greater than the White British group. The proportion of individuals self-identifying as Muslim and Buddhist who had received a vaccine was 79.1% and 84.1%, respectively. Older age, greater area deprivation, less advantaged socio-economic position (proxied by living in a rented home), being disabled and living either alone or in a multi-generational household were also associated with higher odds of not having received the vaccine. Conclusion: People disproportionately affected seem most hesitant to COVID-19 vaccinations. Policy Interventions to improve these disparities are urgently needed.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.13.21257146v1" target="_blank">Sociodemographic inequality in COVID-19 vaccination coverage amongst elderly adults in England: a national linked data study</a>
</div></li>
<li>**HLA-B*15:01 is associated with asymptomatic SARS-CoV-2 infection** -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background. Evidence has shown that a large proportion of SARS-CoV-2 infected individuals do not experience symptomatic disease. Owing to its critical role in immune response, we hypothesized that variation in the human leukocyte antigen (HLA) loci may underly asymptomatic infection. Methods. We enrolled 29,947 individuals registered in the National Marrow Donor Program for whom high-resolution HLA genotyping data were available in a smartphone-based study designed to track COVID-19 symptoms and outcomes. Among 21,893 individuals who completed the baseline survey, our discovery (N=640) and replication (N=788) cohorts were comprised of self-identified White subjects who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci (HLA-A, -B, -C, -DRB1, -DQB1) with asymptomatic vs. symptomatic infection. Results. HLA-B<em>15:01 was significantly increased in asymptomatic individuals in the discovery cohort compared to symptomatic (OR = 2.45; 95%CI 1.38-4.24, p = 0.0016, pcorr = 0.048), and we reproduced this association in the replication cohort (OR= 2.32; 95%CI = 1.10-4.43, p = 0.017). We found robust association of HLA-B</em>15:01 in the combined dataset (OR=2.40 95% CI = 1.54-3.64; p = 5.67 x10-5) and observed that homozygosity of this allele increases more than eight times the chance of remaining asymptomatic after SARS-CoV-2 infection (OR = 8.58, 95%CI = 1.74-34.43, p = 0.003). Finally, we demonstrated the association of HLA-B<em>15:01 with asymptomatic SARS-Cov-2 infection is enhanced by the presence of HLA-DRB1</em>04:01 Conclusion. HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.13.21257065v1" target="_blank">HLA-B*15:01 is associated with asymptomatic SARS-CoV-2 infection</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: GIGA-2050<br/><b>Sponsor</b>:   GigaGen, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: RO7496998;   Drug: Placebo<br/><b>Sponsors</b>:   Atea Pharmaceuticals, Inc.;   Hoffmann-La Roche<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients</strong> - <b>Condition</b>:   COVID-19 Pneumonia<br/><b>Interventions</b>:   Drug: Co-trimoxazole;   Drug: Placebo<br/><b>Sponsor</b>:   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect of Vitamin D Supplementation on COVID-19 Recovery</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol];   Drug: Physiological Irrigating Solution<br/><b>Sponsors</b>:   University of Monastir;   Loussaief Chawki;   Nissaf Ben Alaya;   Cyrine Ben Nasrallah;   Manel Ben Belgacem;   Hela Abroug;   Imen Zemni;   Manel Ben fredj;   Wafa Dhouib<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019COVID-19Pneumonia</strong> - <b>Condition</b>:   Severe COVID-19 Pneumonia<br/><b>Intervention</b>:   Drug: STC3141<br/><b>Sponsors</b>:   Grand Medical Pty Ltd.;   Trium Clinical Consulting<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>tDCS for Post COVID-19 Fatigue</strong> - <b>Condition</b>:   Post Covid-19 Patients<br/><b>Intervention</b>:   Device: Transcranial Direct Current Stimulation<br/><b>Sponsor</b>:   Thorsten Rudroff<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: APX-115;   Drug: Placebo<br/><b>Sponsors</b>:   Aptabio Therapeutics, Inc.;   Covance<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Behavioral: Onsite Point-of-care<br/><b>Sponsors</b>:   Montefiore Medical Center;   The Fortune Society;   University of Bristol<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Breathing Effort in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus</strong> - <b>Condition</b>:   COVID-19 Pneumonia<br/><b>Intervention</b>:   Device: Esophageal catheter<br/><b>Sponsor</b>:   San Luigi Gonzaga Hospital<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Convalescent Plasma as Adjunct Therapy for COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Biological: Convalescent plasma treatment<br/><b>Sponsors</b>:   National Institute of Health Research and Development, Ministry of Health Republic of Indonesia;   Indonesian Red Cross;   Eijkman Institute for Molecular Biology<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Biological: Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)<br/><b>Sponsors</b>:   Dow University of Health Sciences;   Higher Education Commission (Pakistan)<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Recombinant COVID-19 vaccine (Sf9 cells);   Other: Placebo control<br/><b>Sponsors</b>:   Jiangsu Province Centers for Disease Control and Prevention;   WestVac Biopharma Co., Ltd.;   West China Hospital<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACTIV-6: COVID-19 Study of Repurposed Medications</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: Ivermectin Tablets<br/><b>Sponsors</b>:   Susanna Naggie, MD;   National Center for Advancing Translational Science (NCATS);   Vanderbilt University Medical Center<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Remdesivir;   Drug: Conventional<br/><b>Sponsor</b>:   King Edward Medical University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Symprove (Probiotic) as an add-on to COVID-19 Management</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Other: Symprove (probiotic);   Other: Placebo<br/><b>Sponsor</b>:   Kings College Hospital NHS Trust<br/><b>Not yet recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Review of antiviral peptides for use against zoonotic and selected non-zoonotic viruses</strong> - Viruses remain one of the leading causes of animal and human disease. Some animal viral infections spread sporadically to human populations, posing a serious health risk. Particularly the emerging viral zoonotic diseases such as the novel, zoonotic coronavirus represent an actual challenge for the scientific and medical community. Besides human health risks, some animal viral infections, although still not zoonotic, represent important economic loses to the livestock industry. Viral infections…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery</strong> - SARS-CoV-2 causes the pandemic of COVID-19 and no effective drugs for this disease are available thus far. Due to the high infectivity and pathogenicity of this virus, all studies on the live virus are strictly confined in the biosafety level 3 (BSL3) laboratory but this would hinder the basic research and antiviral drug development of SARS-CoV-2 because the BSL3 facility is not commonly available and the work in the containment is costly and laborious. In this study, we constructed a reverse…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction</strong> - SARS-CoV-2 has infected millions of individuals across the globe and has killed over 2.7 million people. Even though vaccines against this virus have recently been introduced, the antibody generated in the process has been reported to decline quickly. This can reduce the efficacy of vaccines over time and can result in re-infections. Thus, drugs that are effective against COVID-19 can provide a second line of defence and can prevent occurrence of the severe form of the disease. The interaction…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings</strong> - The coronavirus disease 2019 (COVID-19) pandemic is caused by newly discovered severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). One of the striking targets amongst all the proteins in coronavirus is the main protease (M^(pro)), as it plays vital biological roles in replication and maturation of the virus, and hence the potential target. The aim of this study is to repurpose the Food and Drug Administration (FDA) approved molecules via computer-aided drug designing against M^(pro)…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Complement inhibition in severe COVID-19 - Blocking C5a seems to be key</strong> - No abstract</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2</strong> - Camostat, nafamostat, and bromhexine are inhibitors of the transmembrane serine protease TMPRSS2. The inhibition of TMPRSS2 has been shown to prevent the viral infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses. However, while camostat and nafamostat inhibit TMPRSS2 by forming a covalent adduct, the mode of action of bromhexine remains unclear. TMPRSS2 is autocatalytically activated from its inactive form, zymogen, through a proteolytic cleavage that…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs</strong> - Plant extracts are rich in bioactive compounds, such as polyphenols, sesquiterpenes, and triterpenes, which potentially have antiviral activities. As a consequence of the coronavirus disease 2019 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, thousands of scientists have been working tirelessly trying to understand the biology of this new virus and the disease pathophysiology, with the main goal of discovering effective preventive treatments and…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Design of advanced siRNA therapeutics for the treatment of COVID-19</strong> - COVID-19 is a newly emerged viral disease that is currently affecting the whole globe. A variety of therapeutic approaches are underway to block the SARS-CoV-2 virus. Among these methods, siRNAs could be a safe and specific option, as they have been tested against other viruses. siRNAs are a class of inhibitor RNAs that act promisingly as mRNA expression blockers and they can be designed to interfere with viral mRNA to block virus replication. In order to do this, we designed and evaluated the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nucleocapsid and Spike Proteins of SARS-CoV-2 Drive Neutrophil Extracellular Trap Formation</strong> - Patients with severe coronavirus disease 2019 (COVID-19) demonstrate dysregulated immune responses including exacerbated neutrophil functions. Massive neutrophil infiltrations accompanying neutrophil extracellular trap (NET) formations are also observed in patients with severe COVID-19. However, the mechanism underlying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced NET formation has not yet been elucidated. Here we show that 2 viral proteins encoded by SARS-CoV-2, the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine</strong> - Hydroxychloroquine (HCQ), the hydroxyl derivative of chloroquine (CQ), is widely used in the treatment of rheumatological conditions (systemic lupus erythematosus, rheumatoid arthritis) and is being studied for the treatment and prevention of COVID-19. Here, we investigate through mathematical modelling the safety profile of HCQ, CQ and other QT-prolonging anti-infective agents to determine their risk categories for Torsade de Pointes (TdP) arrhythmia. We performed safety modelling with…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A SCID mouse-human lung xenograft model of SARS-CoV-2 infection</strong> - SARS-CoV-2 infection, which is responsible for the current COVID-19 pandemic, can cause life-threatening pneumonia, respiratory failure and even death. Characterizing SARS-CoV-2 pathogenesis in primary human target cells and tissues is crucial for developing vaccines and therapeutics. However, given the limited access to clinical samples from COVID-19 patients, there is a pressing need for in vitro/in vivo models to investigate authentic SARS-CoV-2 infection in primary human lung cells or…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm</strong> - Cytokine storm (CS), an excessive release of proinflammatory cytokines upon overactivation of the innate immune system, came recently to the focus of interest because of its role in the life-threatening consequences of certain immune therapies and viral diseases, including CAR-T cell therapy and Covid-19. Because complement activation with subsequent anaphylatoxin release is in the core of innate immune stimulation, studying the relationship between complement activation and cytokine release in…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration</strong> - The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing major threat to global health and has posed significant challenges for the treatment of severely ill COVID-19 patients. Several studies have reported that cytokine storms are an important cause of disease deterioration and death in COVID-19 patients. Consequently, it is important to understand the specific pathophysiological processes underlying how…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro</strong> - Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Psychological Predictors of Precautionary Behaviors in Response to COVID-19: A Structural Model</strong> - The first lines of defense during an epidemic are behavioral interventions, including stay-at-home measures or precautionary health training, aimed at reducing contact and disease transmission. Examining the psychosocial variables that may lead to greater adoption of such precautionary behaviors is critical. The present study examines predictors of precautionary practices against coronavirus disease 2019 (COVID-19) in 709 Mexican participants from 24 states. The study was conducted via online…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323295937">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A COMPREHENSIVE DISINFECTION SYSTEM DURING PANDEMIC FOR PERSONAL ITEMS AND PROTECTIVE EQUIPMENT (PPE) TO SAFEGUARD PEOPLE</strong> - The current Covid-19 pandemic has led to an enormous demand for gadgets / objects for personal protection. To prevent the spread of virus, it is important to disinfect commonly touched objects. One of the ways suggested is to use a personal UV-C disinfecting box that is “efficient and effective in deactivating the COVID-19 virus. The present model has implemented the use of a UV transparent material (fused silica quartz glass tubes) as the medium of support for the objects to be disinfected to increase the effectiveness of disinfection without compromising the load bearing capacity. Aluminum foil, a UV reflecting material, was used as the inner lining of the box for effective utilization of the UVC light emitted by the UVC lamps. Care has been taken to prevent leakage of UVC radiation out of the system. COVID-19 virus can be inactivated in 5 minutes by UVC irradiation in this disinfection box - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN322882412">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>UBIQUITOUS COMPUTING SYSTEM FOR MENTAL HEALTH MONITORING OF PERSON DURING THE PANDEMIC OF COVID-19</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323295498">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>USE OF IMINOSUGAR COMPOUND IN PREPARATION OF ANTI-SARS-COV-2 VIRUS DRUG</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU322897928">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>逆转录酶突变体及其应用</strong> - 本发明提供一种MMLV逆转录酶突变体在野生型MMLV逆转录酶氨基酸序列如SEQ ID No.1序列所示中进行七个氨基酸位点的突变氨基酸突变位点为R205HV288TL304KG525DS526DE531GE574G。该突变体可以降低MMLV逆转录酶对Taq DNA聚合酶的抑制作用大大提高了一步法RTqPCR的灵敏度。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN323494119">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU321590214">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>用于检测新型冠状病毒的试纸和试剂盒</strong> - 本发明涉及生物技术和免疫检测技术领域具体涉及一种用于检测新型冠状病毒的试纸和试剂盒。所述试纸或试剂盒含有抗体1和/或抗体2所述抗体1的重、轻链可变区的氨基酸序列分别如SEQ ID NO:12所示所述抗体2的重、轻链可变区的氨基酸序列分别如SEQ ID NO:34所示。本发明对于大批量的新型冠状病毒样本包括新型冠状病毒突变英国、南非与非突变株的人血清、鼻咽拭子等样本的检测有普遍检测意义避免突变株的漏检。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN322953478">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fahrgastleitsystem und Verfahren zum Leiten von Fahrgästen</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Fahrgastleitsystem zum Leiten von mit einem Fahrzeug (1) mit wenigstens zwei Türen (2.L, 2.R) transportieren Fahrgästen (3), mit wenigstens einem Sensor (4) zur Überwachung der Fahrgäste (3), wenigstens einem Anzeigemittel (5) zur Ausgabe von Leitinformationen, wenigstens einem Aktor zum Öffnen oder Verriegeln einer Tür (2.L, 2.R) und wenigstens einer Recheneinheit (7). Das erfindungsgemäße Fahrgastleitsystem ist dadurch gekennzeichnet, dass die Recheneinheit (7) dazu eingerichtet ist durch Auswertung vom wenigstens einen Sensor (4) erzeugter Sensordaten zu erkennen an welcher Tür (2.L, 2.R) des Fahrzeugs (1) Fahrgäste (3) ein- und/oder aussteigen möchten und wenigstens eine Tür (2.L, 2.R) für einen Ausstieg festzulegen und/oder wenigstens eine Tür (2.L, 2.R) für einen Einstieg festzulegen, sodass eine Anzahl an Begegnungen von sich durch das Fahrzeug (1) bewegender Fahrgäste (3) und/oder aus dem Fahrzeug (1) aussteigenden und/oder in das Fahrzeug (1) einsteigenden Fahrgästen (3) minimiert wird.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289145">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zum Desinfizieren, der Körperpflege oder dergleichen</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung zum Desinfizieren, der Körperpflege oder dergleichen mittels einer flüssigen oder cremigen Substanz (20), dadurch gekennzeichnet, dass die Vorrichtung mit einem elektrisch betriebenen Erinnerungs-Modul und einem Vorratsbehälter (10) für die Substanz (20) versehen ist, die Substanz (20) in dosierter Menge zur Ausgabeöffnung (9) gefördert wird und die Vorrichtung dazu geeignet ist, am Körper oder der Kleidung einer Person getragen zu werden.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289850">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Gebrauchter Schnellteststreifen als Probenmaterial für eine Nachtestung</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Verfahren zur laborbasierten Überprüfung und/oder weiteren Ausdifferenzierung einer im Schnelltestverfahren erhaltenen Diagnose einer Infektionskrankheit, wobei im Rahmen des Schnelltestverfahrens eine flüssige Patientenprobe auf ein Objekt aus einem porösen Material aufgetragen wird und wobei dieses Objekt nach Trocknung der flüssigen Patientenprobe an das diagnostische Labor übermittelt wird. Im Labor werden dann die eingetrockneten Probenreste aus dem porösen Material ausgelöst und analysiert.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE323289151">link</a></li>
</ul>
<script>AOS.init();</script></body></html>